MSD receives FDA approval for Enflonsia to prevent RSV
Pharmaceutical Technology
JUNE 10, 2025
MSD research laboratories president Dean Li stated: “Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight. Give your business an edge with our leading industry insights.
Let's personalize your content